Acta Scientific Biotechnology

Research Article Volume 2 Issue 5

MHC Binding Potential of RBD Domain in Spike Protein of SARS CoV2

Shiny Pravallikan Karukutla and Krupanidhi Sreerama*

Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research, India

*Corresponding Author: Krupanidhi Sreerama, Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research, India.

Received: July 09, 2021; Published: July 29, 2021


SARS-CoV-2 infection became pandemic and public concern due to the outbreak of COVID-19. Since its appearance in Wuhan, China in December 2019 the infection spread across continents. Substantial numbers of global population were disrupted both in their health and family structure. The spike protein is found to be the key protein of coronavirus as it anchors to human alveolar epithelial cells. Hence, the present study is focused on immune informatics analysis of spike glycoprotein (S-protein) of SARS-CoV-2 to explore MHC binding potential of its epitopes. Out of 5058 peptides, each with nine residues obtained through NetMHCpan version 4.1b, six peptides were predicted as epitopes with strong binding potential to HLA-A*02:01, whose distribution is ~33.8% among Indian Asians. Among these six peptides, the amino acid sequence starting from 417th position namely KIADYNYKL was found to be highly probable antigen with a value of 1.6639 derived through VaxiJen V2.0. Peptides predicted in the receptor binding region also revealed that the aforementioned peptide ranked as the strong binder to HLA-A*02:01. The secondary structure prediction of RBD performed through Phyre2 revealed that these peptide residues spanned to stretch in beta strand followed by random coil and reported as immunodominant region using Immunome Browser tool. This study would pave the path to understand the prevalent Delta Plus variant of CoV2 (K417N) and facilitates to design a recombinant vaccine.

Keywords: HLA-A02:01; Spike Protein; SARS CoV2; Delta Plus Variant


  1. Thorsby E. “A short history of HLA”. Tissue Antigens2 (2009): 101-116.
  2. Snell GD. “Studies in histocompatibility”. Science4504 (1981): 172-178.
  3. Dausset J and Soulillou JP. “An interview with Jean Dausset”. American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 1 (2004): 4-7.
  4. Cruz-Tapias P., et al. “Major histocompatibility complex: antigen processing and presentation”. InAutoimmunity: From Bench to Bedside. El Rosario University Press (2013).
  5. Kolla HB., et al. “An immunoinformatics approach for the design of a multi-epitope vaccine targeting super antigen TSST-1 of Staphylococcus aureus”. Journal of Genetic Engineering and Biotechnology1 (2021): 1-4.
  6. Peele KA., et al. “Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2”. Journal of Pharmaceutical Sciences 6 (2021): 2346-54.
  7. Karlapudi AP., et al. “Design of CRISPR-based Targets for the Development of a Diagnostic Method for SARS-CoV-2: An in Silico Approach”. Eurasian Journal of Medicine and Oncology4 (2020): 304-308.
  8. Abraham Peele K., et al. “Design of multi-epitope vaccine candidate against SARS-CoV-2: A in-silico study”. Journal of Biomolecular Structure and Dynamics 27 (2020): 1-9.
  9. Ayyagari VS., et al. “Design of a multi-epitope-based vaccine targeting M-protein of SARS-CoV2: an immunoinformatics approach”. Journal of Biomolecular Structure and Dynamics 16 (2020): 1-5.
  10. Krupanidhi S. “In silico design of multiepitope vaccine candidate against SARS CoV and CoV2”. 7.2 (2020): 61-73.
  11. Reynisson B., et al. “NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data”. Nucleic Acids Research 48 (2020): W449-454.
  12. Doytchinova IA and Flower DR. “VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines”. BMC Bioinformatics1 (2007): 1-7.
  13. Kelley LA., et al. “The Phyre2 web portal for protein modeling, prediction and analysis”. Nature Protocols 6 (2015): 845-858.
  14. Dhanda SK., et al. “ImmunomeBrowser: a tool to aggregate and visualize complex and heterogeneous epitopes in reference proteins”. Bioinformatics22 (2018): 3931-3933.
  16. Mehra NK., et al. “Molecular diversity of HLA‐A* 02 in Asian Indians: predominance of A* 0211”. Tissue Antigens6 (2001): 502-507.


Citation: Shiny Pravallikan Karukutla and Krupanidhi Sreerama. “MHC Binding Potential of RBD Domain in Spike Protein of SARS CoV2”. Acta Scientific Computer Sciences 2.5 (2021): 22-25.


Copyright: © 2021 Shiny Pravallikan Karukutla and Krupanidhi Sreerama. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate35%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US